{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:05:39Z","timestamp":1792076739331,"version":"4.4.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0010696","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000}}],"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Visceral Leishmaniasis (VL) is endemic in South Sudan, manifesting periodically in major outbreaks. Provision of treatment during endemic periods and as an emergency response is impeded by instability and conflict. M\u00e9decins Sans Fronti\u00e8res (MSF) has provided health care in South Sudan since the late 1980\u2019s, including treatment for 67,000 VL patients. In recent years, MSF monitoring data have indicated increasing numbers of VL relapse cases. A retrospective analysis of these data was performed in order to provide insight into the possible causes of this increase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methodology\/Principal findings<\/jats:title>\n                    <jats:p>Programme monitoring data from the MSF hospital in Lankien, Jonglei State, South Sudan, for the period 2001\u20132018 were analysed to detect trends in VL relapse as a proportion of all VL cases presenting to MSF treatment centres. Routinely collected patient-level data from relapse and primary VL cases treated at all MSF sites in South Sudan over the same period were analysed to describe patient characteristics and treatments received. VL relapse as a proportion of all VL cases increased by 6.5% per annum (95% CI 0.3% to 13.0%, p = 0.04), from 5.2% during 2001\u20132003 to 14.4% during 2016\u20132018. Primary VL and VL relapse patients had similar age, sex and anthropometric characteristics, the latter indicating high indices of undernutrition which were relatively constant over time. Clinical factors (Hb, spleen size, and VL severity score) also did not vary substantially over time. SSG\/PM was the main treatment regimen from 2001\u20132018, used in 68.7% of primary and 70.9% of relapse VL cases; AmBisome was introduced in 2013, received by 22.5% of primary VL and 32.6% of VL relapse cases from 2013\u20132018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Increasing incidence of VL relapse in South Sudan does not appear to be explained by changes in patient characteristics or other factors. Our data are concerning and may indicate an emergence of treatment-resistant parasite strains, decreasing the effectiveness of treatment regimens. This warrants further investigation as a causal factor. New chemical entities that will enable safe and highly effective short-course oral treatments for VL are urgently needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0010696","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T13:57:36Z","timestamp":1660831056000},"page":"e0010696","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["The increasing incidence of visceral leishmaniasis relapse in South Sudan: A retrospective analysis of field patient data from 2001\u20132018"],"prefix":"10.1371","volume":"16","author":[{"given":"Gabriel","family":"Naylor-Leyland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon M.","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Gatluak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1598-2206","authenticated-orcid":true,"given":"Margriet","family":"den Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Wasay","family":"Mullahzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5924-872X","authenticated-orcid":true,"given":"Koert","family":"Ritmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"issue":"4","key":"pntd.0010696.ref001","doi-asserted-by":"crossref","first-page":"802","DOI":"10.4269\/ajtmh.16-0279","article-title":"Elimination of Kala-Azar from the Southeast Asia Region","volume":"96","author":"SK Bhattacharya","year":"2017","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pntd.0010696.ref002","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s13071-016-1743-7","article-title":"A review of visceral leishmaniasis during the conflict in South Sudan and the consequences for East African countries","volume":"9","author":"W Al-Salem","year":"2016","journal-title":"Parasit Vectors"},{"issue":"8","key":"pntd.0010696.ref003","article-title":"Control of visceral leishmaniasis in East Africa: fragile progress, new threats","volume":"6","author":"EH Dahl","year":"2021","journal-title":"BMJ Glob Health"},{"issue":"5","key":"pntd.0010696.ref004","doi-asserted-by":"crossref","first-page":"e029141","DOI":"10.1136\/bmjopen-2019-029141","article-title":"Exploring global and country-level barriers to an effective supply of leishmaniasis medicines and diagnostics in eastern Africa: a qualitative study","volume":"9","author":"T Sunyoto","year":"2019","journal-title":"BMJ Open"},{"issue":"11","key":"pntd.0010696.ref005","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug resistance in Indian visceral leishmaniasis","volume":"6","author":"S Sundar","year":"2001","journal-title":"Trop Med Int Health"},{"issue":"4","key":"pntd.0010696.ref006","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1017\/S0031182016002031","article-title":"Evaluating drug resistance in visceral leishmaniasis: the challenges","volume":"145","author":"S Hendrickx","year":"2018","journal-title":"Parasitology"},{"issue":"1","key":"pntd.0010696.ref007","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4269\/ajtmh.2007.77.89","article-title":"Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy","volume":"77","author":"Y Melaku","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"pntd.0010696.ref008","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/infdis\/168.3.715","article-title":"Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone","volume":"168","author":"J Seaman","year":"1993","journal-title":"J Infect Dis"},{"issue":"6","key":"pntd.0010696.ref009","doi-asserted-by":"crossref","first-page":"e1674","DOI":"10.1371\/journal.pntd.0001674","article-title":"Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial","volume":"6","author":"A Musa","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010696.ref010","volume-title":"Control of the leishmaniases: report of a meeting of the WHO Expert Commitee on the Control of LeishmaniasesGeneva, 22\u201326 March 2010","author":"WHO Expert Committee on the Control of the Leishmaniases","year":"2010"},{"key":"pntd.0010696.ref011","volume-title":"Guidelines for diagnosistreatment and prevention of visceral leishmaniasis in South Sudan","author":"Ministry of Health","year":"2011"},{"issue":"1","key":"pntd.0010696.ref012","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/clinids\/21.1.188","article-title":"Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions","volume":"21","author":"J Seaman","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"12","key":"pntd.0010696.ref013","first-page":"1674","article-title":"Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan","volume":"201520","author":"AM Atia","journal-title":"Trop Med Int Health"},{"issue":"3","key":"pntd.0010696.ref014","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40261-016-0481-0","article-title":"Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme","volume":"37","author":"R Kimutai","year":"2017","journal-title":"Clin Drug Investig"},{"key":"pntd.0010696.ref015","volume-title":"Manual on visceral leishmaniasis control","author":"World Health Organization Division of Control of Tropical Diseases","year":"1996"},{"issue":"4","key":"pntd.0010696.ref016","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14728214.2012.748036","article-title":"Liposomal amphotericin B as a treatment for human leishmaniasis","volume":"17","author":"M Balasegaram","year":"2012","journal-title":"Expert opinion on emerging drugs"},{"key":"pntd.0010696.ref017","volume-title":"WHO TRS N\u00b0949. In: Report of a meeting of the WHO Expert Committee on the Control of LeishmaniasesGeneva, 22\u201326 March 2010","author":"World Health Organization: Control of the leishmaniases","year":"2010"},{"issue":"3","key":"pntd.0010696.ref018","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"HJ Kim","year":"2000","journal-title":"Stat Med"},{"issue":"6","key":"pntd.0010696.ref019","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1371\/journal.pntd.0000705","article-title":"Visceral leishmaniasis relapse in Southern Sudan (1999\u20132007): a retrospective study of risk factors and trends","volume":"20104","author":"S Gorski","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0010696.ref020","doi-asserted-by":"crossref","first-page":"e2536","DOI":"10.1371\/journal.pntd.0002536","article-title":"Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg\/kg liposomal amphotericin B (Ambisome) in Bihar, India","volume":"8","author":"S Burza","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010696.ref021","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijid.2020.02.028","article-title":"Predictors of relapse of visceral leishmaniasis in inner Sao Paulo State, Brazil","volume":"95","author":"JC Simao","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"2","key":"pntd.0010696.ref022","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-3156.2010.02694.x","article-title":"Risk factors for relapse of visceral leishmaniasis in Georgia","volume":"16","author":"M Kajaia","year":"2011","journal-title":"Trop Med Int Health"},{"key":"pntd.0010696.ref023","doi-asserted-by":"crossref","first-page":"3513957","DOI":"10.1155\/2019\/3513957","article-title":"Visceral Leishmaniasis Treatment Outcome and Associated Factors in Northern Ethiopia","volume":"2019","author":"K Gidey","year":"2019","journal-title":"Biomed Res Int"},{"issue":"7","key":"pntd.0010696.ref024","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.trstmh.2008.09.008","volume":"103","author":"RN Davidson","year":"2009","journal-title":"Paromomycin. Trans R Soc Trop Med Hyg"},{"issue":"1","key":"pntd.0010696.ref025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trstmh.2006.02.005","article-title":"Unresponsiveness to AmBisome in some Sudanese patients with kala-azar","volume":"101","author":"M Mueller","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"6","key":"pntd.0010696.ref026","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/clinids\/22.6.938","article-title":"Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)","volume":"22","author":"RN Davidson","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pntd.0010696.ref027","first-page":"75","article-title":"Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial","volume":"87","author":"RN Davidson","year":"1994","journal-title":"Q J Med"},{"issue":"1","key":"pntd.0010696.ref028","doi-asserted-by":"crossref","first-page":"e2613","DOI":"10.1371\/journal.pntd.0002613","article-title":"Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial","volume":"8","author":"EA Khalil","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0010696.ref029","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1086\/340219","article-title":"Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1","volume":"185","author":"MA Morales","year":"2002","journal-title":"J Infect Dis"},{"issue":"9","key":"pntd.0010696.ref030","doi-asserted-by":"crossref","first-page":"e0007726","DOI":"10.1371\/journal.pntd.0007726","article-title":"Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India","volume":"13","author":"V Goyal","year":"2019","journal-title":"PLoS Negl Trop Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0011952","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000}},{"DOI":"10.1371\/journal.pntd.0010696","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T21:30:56Z","timestamp":1727818256000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010696"}},"subtitle":[],"editor":[{"given":"Mitali","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0010696","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]}}}